On March 28, 2023, Shanghai Leadingtac Pharmaceutical Co., Ltd. (hereinafter referred to as "Leadingtac Biotech") announced that it has officially submitted an IND clinical trial application to the U.

In October 2022, the Shanghai Science and Technology Commission awarded the honorary certificate of being selected as one of the "Shanghai Pujiang Talent Program Projects" for 2022.

On November 15, the first "Zhangjiang Life Science Industry Annual Emerging Talent" award was announced at the "Zhangjiang Life Science International Innovation Summit" in Pudong New Area, which focuses on recognizing emerging talents and enterprises that have made breakthroughs in "science, new discoveries, new inventions, new directions in industry and new ideas" since 2021. The award focuses on the new breakthroughs in "new discoveries, new inventions in technology, new directions in industry and new ideas in development" since 2021. Dr. Yan Feng was awarded as the "Zhangjiang Life and Health Industry Emerging Person of the Year".

In September 2022, Shanghai Municipal Science and Technology Commission announced the projects for Shanghai 2022 Technology-based SME Technology Innovation Fund Program. After a strict selection and tough competition by the Expert Committee of Shanghai Municipal Science and Technology Commission, Shanghai Leadingtac Pharmaceutical Co., Ltd. declared "Protein Degrader innovative drug LT002 preclinical study".

On September 7, the award ceremony and the policy propaganda of the first season of biomedical "Stars of Tomorrow" was held in Zhangjiang Artificial Intelligence Island. Liu Ping, Deputy Director of the Municipal Economic Information Technology Commission, attended and presented awards to the winning companies.

ME&WE | (Video) Yan Feng of Leadingtac: Advancing targeted protein degradation technology, blazing a "new path" to druggability.

Following the accreditation of the key institution of "Zhangjiang Science Park", employees are eligible for the benefits of talent settlement policy, mainly in the residence permit settlement and talent introduction program.

(hereinafter referred to as Leadingtac Bio), a company in Zhangjiang Science City announced the completion of a Pre-A round of financing led by Yuan Sheng Venture Capital, with additional investment from long-time shareholder ZJ LEADING VC. This funding round will be used primarily to advance the company's first Protein Degrader pipeline for autoimmune disease treatment to the clinical research stage and to develop follow-on programs and pipelines, including oncology and other autoimmune diseases. With the previous angel round, Leadingtac has raised nearly 100 million RMB in cumulative early-stage financing.

At the end of 2019, a new team, Leadingtac Bio, emerged on the track of targeted protein degradation in Zhangjiang Pharmaceutical Valley, Pudong, Shanghai. This company focuses on the research and development of new small- molecule drugs in autoimmune and oncology diseases. Although it was infant, its founder, Yan Feng, was already one of the pioneers of innovative drug development in China in 2005.